;) |
IMGM: Imagin Molecular Corp.
An Explosive Opportunity as the U.S. Medical Imaging Market Nears $7 Billion
The medical imaging equipment market in the U.S. will register gains of 7.6 percent per year through 2008 to 9.5 billion, faster than projected growth in national health expenditures. Growth will be stimulated by an increasing incidence of patient procedures involving diagnostic imaging, partly the result of and aging population and partly reflecting advances in innovative imaging technology. Our featured company IMGM through its wholly owned subsidiary Imagin Nuclear Partners is a full service joint venture molecular imaging partner with a business model based on owning, operating, and administering out-patient medical diagnostic imaging centers that utilize PET and PET/CT (computed tomography) scanning equipment.
IMGM'S TARGET MARKET
IMGM's target market is community hospitals which comprise 81% of the overall U.S. hospital market and private medical imaging practices. IMGM seeks to create joint ventures that own, operate, and manage Positron Emission Tomography (PET) diagnostic imaging centers within these hospitals. By creating these “in house” imaging centers, these hospitals can recapture revenue that is often lost or outsourced to independent medical diagnostic entities.
7 Day Price and Volume as of 1/6/2006
|
January 9, 2006 Issue #109
Shares Outstanding: 44,323,732
Float (Estimate): 6,356,579
Current Price: $0.235▲ |
CORPORATE SNAPSHOT
Imagin Molecular Corp. (OTCBB: IMGM) is a Deleware corporation headquartered in Oak Brook, IL that is dedicated to business opportunities in the area of Positron Emission Tomography (PET). PET is a diagnostic technology used in oncology, cardiology, and neurology.
WHAT IS PET IMAGING
Positron Emission Tomography (PET) is a powerful imaging technique that holds great promise in the diagnosis and treatment of many diseases, particularly cancer, heart disease, and neurological disorders. A non-invasive test, PET scans accurately image the cellular function of the human body. In a single PET scan your physician can examine your entire body. PET scanning provides a more complete picture, making it easier for your doctor to diagnose problems, determine the extent of disease, prescribe treatment, and track progress.
STRATEGIC ALLIANCE
IMGM through its other wholly owned subsidiary PAC owns a 64 million share convertible preferred note in Positron Corporation (OTCBB: POSC) with an approximate market value of $6 million upon conversion. Positron Corporation engages in the design, manufacturing, marketing, and servicing of advanced medical imaging devices using PET technology.
INVESTMENT CONSIDERATIONS
- The U.S. market for medical imaging equipment is estimated to grow 7.6% annually through 2008 driven by more procedures involving diagnostic imaging.
- IMGM is designed to enable smaller community hospitals to recapture revenues lost to outsourcing.
- In the U.S. in 2004, approximately 290,220 PET/CT procedures were projected to have been completed, up 175% from the 105,375 PET/CT's completed in 2003. That number is projected to grow to nearly 2 million annually over the next 6 years (Source: Frost and Sullivan).
|
| This report is for information purposes only, and is neither a solicitation or recommendation to buy nor an offer to sell securities. OTC InfoWire is a registered investment advisor. OTC InfoWire is not a broker-dealer. Information, opinions, price targets, and analysis contained herein are based on sources believed to be reliable, but no representation, expressed or implied, is made as to its accuracy, completeness or correctness. The opinions contained herein reflect our current judgment and are subject to change without notice. OTC InfoWire accepts no liability for any losses arising from an investor's reliance on the use of this report. The principal of OTC InfoWire has been compensated 200,000 free trading shares of IMGM by a third party consultant, and OTC InfoWire has been compensated by a third party consultant and is contracted to receive $10,000 for the publication and circulation of this report. OTC InfoWire and its affiliates or officers may buy, hold, but most likely will sell shares of common stock of IMGM, in the open market at any time without notice. Certain information included herein is forward-looking within the context of the Private Securities Litigation Reform Act of 1995, including, but not limited to, statements concerning manufacturing, marketing, growth, and expansion. The words "may", "would," "will," "expect," "estimate," "anticipate," "believe," "intend," “ project,” and similar expressions and variations thereof are intended to identify forward-looking statements. Such forward-looking information involves important risks and uncertainties that could affect actual results and cause them to differ materially from expectations expressed herein. *OTC InfoWire does not set price targets on securities. |